Last $3.34 USD
Change Today +0.02 / 0.60%
Volume 60.0K
STXS On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/13 - $10.18
52 Week Low
07/16/13 - $1.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive Robotic Navigation System, which offer navigation and stability for the diagnostic and ablation devices that assist in delivery of ablations. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks; acquires a real-time remote view of the lab capturing synchronized procedure data for the review of events during cases; enable physicians to access recorded cases and create snapshots following procedures for clinical reporting, auditing, and presenting; and enables physicians to establish a master archive of procedures performed in the lab. In addition, it provides disposables and other accessories, such as Cardiodrive or QuikCAS automated catheter advancement disposables for the advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Titan and Pegasus coronary guide wires for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. It has strategic alliances with Siemens AG Medical Solutions, Philips Medical Systems, and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

123 Employees
Last Reported Date: 03/27/14
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $370.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $192.5K
Senior Vice President of Marketing & Business...
Total Annual Compensation: $285.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $270.0K
Vice President of Human Resources
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

stereotaxis inc (STXS) Key Developments

Stereotaxis Inc. Submits 510(K) Application to FDA for Vdrive With V-CAS Catheter Advancement System

Stereotaxis Inc. announced that it has submitted a 510(k) Premarket Notification to the Food and Drug Administration (FDA) for the company's Vdrive(TM) Robotic Navigation System with V-CAS(TM) Catheter Advancement System. The submission, which follows the Company's 510(k) application for Vdrive with V-Loop(TM) Variable Loop Catheter Manipulator on March 31, includes both the single-arm system (Vdrive) and the two-arm system (Vdrive Duo). The Vdrive with V-CAS system is currently available in the European Union and Canada and has been used in more than 1,100 procedures since its introduction in 2011. The system allows physicians to remotely control the advancement, retraction and rotation of a compatible fixed curve transseptal sheath, in conjunction with a magnetic ablation catheter. Utilized in the majority of ablation procedures, the fixed curve transseptal sheath provides greater stability and support to the ablation catheter during therapy delivery.

Stereotaxis Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Stereotaxis Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue totaled $8.4 million, unchanged from the prior year first quarter. Operating loss was $2.2 million, a 38.0% improvement from $3.6 million in the prior year quarter. Net loss was $4.1 million, or $0.21 per share, compared to a net loss of $4.9 million, or $0.61 per share, reported in the first quarter of 2013. Excluding mark-to-market warrant revaluation, the first quarter 2014 net loss would have been $3.1 million, or $0.16 per share. Excluding mark-to-market warrant revaluation and amortization of convertible debt discount, the first quarter 2013 net loss would have been $5.0 million, or $0.63 per share.

Stereotaxis Inc. to Report Q1, 2014 Results on May 06, 2014

Stereotaxis Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $3.34 USD +0.02

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $0.69 USD -0.01
Biolase Inc $1.97 USD -0.01
Synergetics USA Inc $3.02 USD +0.02
Uroplasty Inc $2.63 USD -0.01
Vision Sciences Inc/DE $1.17 USD -0.0351
View Industry Companies

Industry Analysis


Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at